Mei Liu

11PUBLICATIONS
15CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyMolecular targetsInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 05, 2026
Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases.

|Apr 27, 2026
Cholesterol Reprograms Oxysterol Metabolism via the LOX1/CH25H/CYP7B1 Signaling Axis to Drive Multidrug Resistance in Colorectal Cancer.

|Mar 30, 2026
Cancer-Associated Fibroblasts in the Treatment of Intrahepatic Cholangiocarcinoma: Present and Prospects.

Yimeng Yuan, Ruoyu Zhang, Chengkang Qu

|Jan 09, 2026
VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway.

Jiajun Zhang, Ning Huang, Lin-Rui Gao

|Jun 05, 2024
The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma.

Shuwen Kuang, Jiajun Zhang, Ning Huang

|Mar 26, 2024
Human Endometrium Derived Mesenchymal Stem Cells with Aberrant NOD1 Expression Are Associated with Ectopic Endometrial Lesion Formation.

Chunmei Li, Suiyu Luo, Ai Guo

Pageof 2

Frequent Collaborators

3 joint publications

Ning Huang

3 joint publications

Liming Wang

1 joint publications

Chunmei Li

1 joint publications

Suiyu Luo